Research programme: cancer and infectious disease therapeutics - Inhibikase Therapeutics

Drug Profile

Research programme: cancer and infectious disease therapeutics - Inhibikase Therapeutics

Alternative Names: Anti-bacterial AblKi; EGFRi HepC; IkT-004; IkT-014; IkT-041; IkT-061; IkT-064; PML SAR; Virus-similar particle vaccine; VSP vaccine

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inhibikase Therapeutics
  • Class Small molecules; Viral vaccines
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Viral infections
  • Research Hepatitis C; Polyomavirus infections
  • No development reported Diarrhoea; Respiratory tract infections
  • Discontinued Influenza A virus infections

Most Recent Events

  • 29 Jun 2015 Inhibikase Therapeutics receives SBIR grant from the U.S. National Institutes of Health for development of Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry programme in Cancer
  • 23 May 2014 Preclinical development is ongoing for Viral infections for biodefense applications, and development is still at the early research stage for other viral and bacterial infections
  • 30 Apr 2013 Discontinued - Preclinical for Influenza A virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top